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QUANTITATIVE ANALYSIS OF BLEOMYCIN IN RATS PLASMA  
WITH LC-MS/MS 
HUAWEN LI 
ABSTRACT 
Bleomycin is the most commonly used compound in its group of antineoplastic 
drugs. It works on tumor cells by single and double stranded DNA cleavage after its 
activation, in which it blocks tumor cells’ DNA replication or transcription activities to 
inhibit tumor cells’ growth. Bleomycin sulfate (Blenoxane) is the most popular 
preparation used in clinical research, and contains Bleomycin fractions of A2 and B2, 
which causes difficulties in quantitative analysis. This work uses the metal chelating 
property of Bleomycin as an advantage to simplify and improve sensitivity of existing 
quantitative methods. 
Copper was spiked in excess to plasma samples, followed by liquid-liquid 
extraction. Samples were then subjected to analysis by high-performance liquid 
chromatography electrospray ionization tandem mass spectrometry using a quadrupole 
trap mass analyzer. Samples spiked with copper showed improved selectivity over 
samples without excess copper, thereby making use of standard mass spectrometers a 
possibility in the clinic. In comparison with current methods of quantification of 
Bleomycin in plasma, this method achieved higher percent recoveries of the 
chemotherapy drug, higher sensitivity of quantification, with lower matrix effects, as well 
as a more simple preparation method. Linear range in the lower nanogram per milliliter 
range with a correlation coefficient over 0.99 makes this method promising for improved 
quantification and monitoring of Bleomycin in plasma.  
vi 
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CHAPTER I 
INTRODUCTION 
1.1 Blenoxane 
Bleomycin sulfate (Blenoxane; BLM; DB00290; Fig. 1)
3
 is a widely used drug in 
oncology used to treat a variety of cancers, such as Hodgkin’s and non-Hodgkin’s 
lymphoma, testicular cancer, ovarian cancer, and cervical cancer among others.
1
 BLM is 
also used as a highly effective cytostatic antibiotic. In its use as an anticancer agent, BLM 
can be given intravenously by injection into the muscle or under the skin.
1
 The advantage 
of the BLM compared to other chemotherapeutic drugs and other drugs in its class 
includes use in multi-cancer therapy, fewer side effects, and that it is not damaging to the 
bone marrow and the immune system.
1, 2, 3
 Bleomycin was discovered in 1962, and the 
most widely used drug is isolated from the fermentation broth of Streptomyces verticillus. 
Current clinically administered preparations of the drug mixture has more complex 
contents. The most common Bleomycin drug is the Bleomycin sulfate (Blenoxane), 
which mainly consists of metal (Cu) ions, 55-70% of Bleomycin A2 [molecular weight 
(M.W.) of 1414.52], and 25-32% of Bleomycin B2 (molecular weight of 1424.56).
2,3
 The 
rationalization as to when bleomycin sulfate is used as a treatment in clinical use is with a 
2 
deep consideration of its toxicity; therefore the research on its side effect from hydrolysis 
studies is an interest of some research groups.  
 
 
 
Figure 1. The chemical structure of bleomycin sulfate. IUPAC name: {(3-{[2-(2-{2-
[(2S,3R)-2-[(2S,3S,4R)-4-[(2S,3R)-2-({6-amino-2-[( 1S)-1-{[(2S)-2-amino-2-
carbamoylethyl]amino}-2-carbamoylethyl]-5-methylpyrimidin-4-yl}formamido)-3-[(3-
{[4-(carbamoyloxy)-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-4,5-dihydroxy-6-
(hydroxymethyl)oxan-2-yl)oxy]-3-(1H-imidazol-5-yl)propanamido]-3-hydroxy-2-
methylpentanamido]-3-hydroxybutanamido]ethyl}-1,3-thiazol-4-yl)-1,3-thiazol-4-
yl]form-amido}propyl)dimethylsulfanium}.
3,4
 
 
1.2 Overview of Research on Bleomycin 
It is important to understand the mechanism and metabolism of Bleomycin, not 
only for its biochemical mechanism of DNA damage knowledge but also to be able to 
accurately quantify this significant anticancer drug for clinical use. The most commonly 
3 
used Bleomycin sulfate preparation contains two main fractions, as well as chelating 
copper (II) ions. A clearly understood mechanism and metabolic pathway facilitates the 
generation and development of clinically relevant treatments and diagnostic 
methodologies, for example the production of agonists and antagonists that reduce harm 
to patients from its side effects and moreover analytical methods can also be developed to 
improve quantification, diagnosis, and therapeutic monitoring all more accurately and 
precisely. 
Bleomycin, a glycoprotein, that is comprised of two sugar rings and a polypeptide 
chain if four amino acids in length (Fig. 2). Five amino groups confer the molecule’s high 
polarity. It is documented that the anticancer properties of Bleomycin must be activated 
by incorporation with metal ions and free molecular oxygen.
6
 Bleomycin can be activated 
by a metal binding ions and oxygen molecules enabling it to react with double stranded 
DNA, specifically with deoxyguanosine-phosphate-deoxycytosine (GpC) and 
deoxyguanosine-phosphate-thymidine (GpT) residues, which then produces a 
pseudoenzyme and hydroxide free radicals, thereby cleaving both strands of DNA. 
Bleomycin hydrolase is the only enzyme that is known to metabolize Bleomycin on its α-
amino-carboxylamide group. Bleomycin hydrolase is a cytosolic cysteine proteinase 
enzyme that is widely distributed in normal tissues except for the skin and lungs, in 
which case, targets of Bleomycin toxicity cause extreme side effects.  
4 
 
Figure 2. The structural contents of bleomycin sulfate.
5
 Bleomycin hydrolase converts 
Bleomycin to desamido-bleomycin, which presents as its fifth coordinate nitrogen is 
replaced by a carboxyl group, decreasing the oxygen activating affinity of the 
Bleomycin-Fe(II) complex resulting in the loss of Bleomycin’s activity. In this case, 
bleomycin’s 5’-amine might be the key to control the activity of Bleomycin. 
 
1.3 Mechanism of Action 
 Bleomycin is a structurally complex compound containing distinct regions that 
participate in the compound’s biological activity. Bleomycin sulfate structure is divided 
into three domains: Metal-binding domain, two sugar moieties, and DNA binding 
domain. The metal-binding domain binds a metal ion and an oxygen molecule to activate 
bleomycin. The sugar moieties facilitate uptake into the cellular membrane for drug 
delivery. And lastly, the DNA binding domain, a bithiazole, specifically identifies and 
5 
binds to deoxyguanosine at the minor groove of both single- and double-stranded DNA, 
which is the precursor step to cleave DNA strands. 
1.3.1 Metal-Binding Domain 
 In the metal-binding domain, only the deprotonated amide nitrogen binds to the 
metal biding site.
5
 The metal-binding domain can bind a variety of metal ions, however 
Cu(II) has the highest coordinate affinity and BLM is most often found as a complex with 
Cu(II). Once the activated bleomycin that binds with Cu(II) is transported into the cells, 
Cu(II) is converted into Cu(I) by intracellular reductants and then is unbounded from 
BLM-Cu complex and is converted back to free BLM (Fig. 3).
6
 Intracellular Fe(II) binds 
to BLM on its metal-binding domain at the deprotonated amide nitrogen sites, then the 
complex is oxidized to BLM-Fe(III)-OOH
-
, thereby releasing hydroxide free radicals that 
cleave DNA. BLM-Fe(III) is then converted to BLM-Fe(II) by intracellular reductants as 
NADH, ascorbic acid, or 2-hydroxy-1-ethanethiol (Fig. 4).
7,8
 
6 
 
Figure 3. The pathway of bleomycin transportation into the cell and its metal-binding 
condition. Bleomycin sulfate binds to Cu(II) as an extracellular activation to be 
transported into the cell. Cu(II) ion is unbound in the cell, and bleomycin then binds to 
the Fe(II), and then to be oxidized to a BLM-Fe(III)-OOH
-
 to release hydroxide free 
radicals to catalyzing DNA cleavage in the cell nucleus.
6,7,8
 
 
Figure 4. Hypothesis of catalyzing BLM-Fe(II) complex by oxygen.
8
 
7 
1.3.2 Sugar 
Glucose and mannose form a disaccharide structure that does not directly bind to 
the DNA. This structure’s purpose is to stabilize the BLM-Fe complex, and enhance the 
drug’s uptake into the biological membrane. 
1.3.3 DNA Binding Domain 
The DNA binding domain is a bithiazole structure, which is the main structure 
that binds to the DNA. The bithiazole preferentially identifies the Guanine nucleobase of 
DNA.
8
 Bithiazole has properties of aromaticity and coplanarity. Since it identifies 
Guanine of the DNA, it inserts specifically between both single or double strand 
deoxyguanosine-phosphate-deoxycytosine and deoxyguanosine-phosphate-thymidine at 
the minor groove to make an interlayer complex.
9
 BLM-Fe-OO extracts a hydrogen atom 
from the 4’ carbon of the guanosine-connecting deoxyribose then reacts with the oxygen 
free radical to break the chain.
9
 The identification of products indicates that there are two 
pathways that activate BLM-Fe to induce the mechanism of DNA cleavage. When there 
is excess of oxygen, the 4’ carbon hydroperoxide intermediate is produced as base-
propenal to break the deoxyribose.
8
 In a hypoxic enviornment, the dissociative base can 
be detected. The bond between 3’-phosphate and 3’ carbon of deoxyribose breaks to 
cleave the chain, and oxygen on the deoxyribose breaks with 4’ carbon to produce the 
dissociated base radical (Fig. 5).
8
 
8 
 
Figure 5. Two pathways that BLM-Fe(II)-O2 catalyzes DNA cleaverage.
8
 
 
1.4 Metabolism 
The metabolism and distribution of BLM hydrolase in an organism’s body is the 
main cause of some adverse side effects including conditions of the lung, fibrosis and 
rash development. To reduce the side effects, current research groups are investigating 
the hydrolysis pathway of Bleomycin and toxic effect dosage by employing analytical 
techniques such as chromatography and spectroscopy with statistical analyses to gain 
information on target molecule distribution on organs and toxicity. 
Bleomycin hydrolase is the only enzyme that inactivates bleomycin. Bleomycin 
hydrolase is a group of cytosolic cysteine proteinase enzymes that are widely distributed 
in normal tissue with the exception of the skin and lungs, which causes extremely toxic 
side effects in these areas which include fibrosis of the lung tissue and rashes.
3
 BLM 
hydrolase metabolizes BLM on its α-amino-carboxylamide to loose and amide to produce 
product as desamido-bleomycin (desBLM). In desBLM, Fe(II) ion binds to the carboxyl 
group instead of a nitrogen, thereby decreasing the oxygen activating affinity of this 
9 
desBLM-Fe(II) complex, in which case desBLM-Fe(II) complex weakens or loses its 
ability to release oxygen free radicals to fail on DNA cleavage. 
 
Figure 6. Change of metal-binding site of desamido-bleomycin. BLM hydrolase 
metabolizes BLM on its α-amino-carboxylamide. Desamido-bleomycin then changes its 
metal-binding site into the carboxyl group instead of nitrogen, thereby decreasing the 
oxygen activating affinity of this desBLM-Fe(II) complex. 
 
1.5 Consideration of Bleomycin Quantitative Analysis 
 Most assays for the quantification of Bleomycin employ techniques with poor 
sensitivity such as ultraviolet or fluorescent detection or radioimmuno-assays. Current 
quantification mostly uses liquid chromatography (LC) with fluorescence or ultraviolet 
(UV) detection. Detector of UV is limited to where saturated organic compound 
transitions occur. Also, only π-π and p-π conjugated unsaturated esters absorb in the near 
UV band. The first group to publish a method for the analysis of Bleomycin by HPLC 
was Shiu and Goehl
10
 in 1980 followed by Mahdadi et al.
11
 a decade later who published 
a more sensitive method with a fluorescence detector and ion-paring reverse phase HPLC. 
These two methods were only validated for the A2 fraction and in addition only achieved 
a sensitivity of 70 nanograms per milliliter, which is not sufficient for detection in human 
plasma. In 2012 Mabeta et al.
12
 developed a HPLC method for separation and 
quantification of both A2 and B2 fractions, however this method had several weaknesses, 
10 
in that it had a narrow linear range and the actual BLM concentration would exceed their 
upper limit of quantification.  
Mass spectrometry is able to overcome these limitations of other detection 
methods and is unparalleled in the quantification of small molecule metabolites. Tandem 
mass spectrometry ensures confidence in quantification and the highest selectivity. The 
biggest advantage in using MS/MS is no need to consider about separating impurities. 
The dosage of Blenoxane is about 0.25-0.50 units/kg, and it would reach peak plasma 
concentration (1-3ug/mL) in 30-60 minutes. The terminal half-life is approximately 3 
hours, and about 65% of administered intravenous dosage is excreted in urine within 24 
hours. MRM channel has enough sensitivity (pg/mL) to quantify such low level of 
concentration. 
Although several research groups have developed LC-MS methods to determine 
the concentration of BLM in plasma samples, these methods have low selectivity and 
would present a problem in the presence of analytes of similar structure. More successful 
methods such as Galba et al.
13
 and Kosjeck et al.
14
 rely on high resolution mass analyzers 
(Q-TOF; quadrupole-time-of-flight) to elucidate quantitative peaks in a complex spectra 
of many isotopic patterns. Such instruments are not readily available nor widespread in 
the clinical setting. The methods mentioned also require time consuming sample 
preparation steps or uncommon chromatography conditions, making the methods 
impractical. Since there does not exist a simple and accessible method for the 
quantification of Bleomycin in plasma, development of such method is in need as the 
ability to quantify the chemotherapeutic drug in plasma is important in determining the 
11 
therapeutic window of the drug as well as toxicity in addition to monitoring the efficacy 
of therapy. 
1.6 Aims and Objectives 
The objective of this project is to design a method to quantify BLM-Cu complex 
in plasma, overcoming its low concentration and multiple formations. The purpose of 
analyzing activated BLM is for its clinical utility and it is thus important to convert all 
BLM into BLM- Cu
2+
 complex. As same molecular weight with desBLM and BLM, the 
targets on BLM-Cu
2+
 complex would also eliminate the interference of desBLM to the 
final quantitation of BLM. 
Specifically the methods developed aims to reduce the interference and instability 
of BLM and increase the sensitivity by transferring all non-metal binding BLM into 
metal binding BLM. The second aim is to utilize widely-available LC-MS 
instrumentation that is translatable to the clinical setting, therefore the method was 
developed using LC-ESI-triple-quadruple mass spectrometer with appropriate conditions. 
1.7 Method Development 
 This method was developed to utilize a quick and efficient extraction technique, 
liquid-liquid extraction, in order to reduce effect matrix, and improve sensitivity of LC-
MS/MS detection, which realizes high sensitivity, high selectivity, and reduced loss of 
analyte in the process of the analysis. The cost of mass spectrometer is high; however, it 
satisfies the highest sensitivity and selectivity of the analysis with its MRM channel. The 
solvent buffer and mobile phases does not contain complex contents, which is easily 
prepared and remained stable. To extract analytes from the plasma samples, only simplest 
12 
protein precipitation by using high concentration of methanol would satisfy high recovery 
of the analysis. 
1.7.1 Liquid-Liquid Extraction 
 BLM is highly polar and easily dissolved in water and methanol, and there is no 
effect with the proteins in plasma. In this method, 70% and higher concentration of 
methanol is prepared for protein precipitation. After ice-dry evaporation and 
concentration with 20% methanol, the working solutions would remain ＞95% of the 
original spiked BLM. In comparison with solid-phase extraction, liquid-liquid extraction 
saves solid-phase column and complicated extraction procedures. 
1.7.2 Mass Spectrometry 
 Mass spectrometry provides qualitative and quantitative information about the 
atomic and molecular composition of inorganic and organic materials. The mass 
spectrometer produces charged particles that consist of the parent ion and ionic fragments 
of the original molecules. The mass analyzer then sorts these ions according to their 
mass/charge ratio. The mass spectrum is a record of the relative numbers of different 
kinds of ions and is characteristic of every compound, including isomers. In tandem 
quadrupole MS, collision induced dissociation in the second quadrupole cell, Q2, and 
selection of fragments of parent ion in the ion trap is advantageous in the quantitative 
analysis of compound in solvent. 
Electrospray ionization (ESI) is a soft ionization technique that produces ions 
using an electrospray in which a high voltage is applied to a liquid to create an aerosol. 
As use of MALDI, ESI is especially useful to produce ions from macromolecules because 
it overcomes the propensity of these molecules to fragment when ionized. A solution of 
13 
macromolecules is sprayed in the form of fine droplets from a glass capillary under the 
influence of a strong electrical field. The droplets pick up charge as they exit the 
capillary, and the evaporation of the solvent leaves highly charged molecules. Since 
droplets “break down” to form spray and evaporate, the charge increases many times 
until the gas-phase molecules or fragments finally enter the analyzer. The ESI is mostly 
used to analyze thermo-instable polar macromolecules, and the sample molecules hardly 
disintegrate during the ionization. Slower flow rate causes more fragments via ionization, 
furthermore contributing to the high degree of sensitivity. However, ESI limits the 
molecular structures, which easily cause thermo-dissociation. The chemical noise 
presents clearly since the molecular mass is low. It is also not suitable for large M.W. 
molecules which larger than 1000Da, but this can be fixable by changing flow rate. The 
molecular weight limit is too small for Bleomycin which averages as ~1414Da. However 
this is overcome by the ability of ESI to form multiple charges. At +2 charges channel, 
that has satisfied the molecular weight limit and the drug can be detected in the spectrum 
although the spectrum does not show the singly charged compound. 
1.7.3 High-Performance Liquid Chromatography (HPLC) 
HPLC is widely used to separate mixed compounds based on their polarities. 
HPLC consists of liquid mobile phases and a stationary phase that can be reused. It uses 
high pressure to ensure the mobile phase quickly passes through the stationary phase 
packed in the column. It has a quicker flow rate and more rapid analysis than traditional 
liquid chromatography. It is highly effective and highly sensitive to analyze low 
concentration of analytes (0.01 ng). 
14 
The mostly commonly used stationary phase in HPLC is reverse phase columns, 
which strongly retain polar compounds on the column and eluted with reversed polarity 
of mobile phases to realize high selectivity. In combination with tandem quadrupole MS, 
the LC-MS/MS system delivers the highest selectivity of separating compounds from 
complex biological matrices and with little to no interference from compounds of the 
same molecular weight as the target analytes. In this method, the column specially used is 
a SYNERGI
TM
 HYDRO-RP Polar Endcapped C18 Column (Fig. 7), which specializes in 
the application for extreme retention of non-polar and extremely polar alkyl compounds. 
The mobile phase A is 20mM of ammonium formate and 0.1% of formic acid and mobile 
phase B is 0.1% of formic acid in 100% of methanol. The elution appears to be polar with 
time gradients of 20-60% of mobile phase B. 
 
Figure 7. Structure of SYNERGI
TM
 HYDRO-RP Polar Endcapped C18 Column. On the 
inter-surface of the column, there are C18 and polar site, which presents good retention 
on both polar and non-polar compounds.
15
  
15 
 
 
 
 
 
CHAPTER II 
MATERIALS AND METHODS 
2.1 Chemicals and Solutions 
 Blenoxane was purchased from Alexis Biochemicals, in which contains ~67% of 
BLM A2 and ~29% of BLM B2. The internal standard Vancomycin hydrochloride (VCM) 
was purchased from Sigma Aldrich (St. Louis, MO). Methanol (≥99.9%) and ammonium 
formate ((≥99%) were purchased from Sigma Aldrich (St. Louis, MO). Water is purified 
using the Millipore Milli-Q system (Milford, MA). Formic acid was purchased from 
Fluka. 
 Mobile phase A is prepared by dissolving ~0.63g of ammonium formate and 1mL 
of concentrated formic acid into 1L of DI-water, which is prepared as 20mM of 
ammonium formate and 0.1% formic acid. Mobile phase B is prepared as 0.1% formic 
acid by dissolving 1mL of formic acid into 1L of 100% methanol. 
2.2 Sample Preparation 
 Two groups of rat plasma were generously provided by a research group at 
Cleveland Clinic Lerner Research Institute. In 2012, the lab in Cleveland Clinic Lerner 
Research Institute commenced a project that injecting BLM into the lungs and bronchia 
of rats, and records the condition of lung fibrosis by timekeeping. Eight rats at an age of 
16 
eight weeks old were injected with 25mg of BLM into lungs and bronchia while the other 
six were kept as controls. After 14 or 28 days, plasma samples were collected and 
0.5mL/L EDTA was treated. All plasma samples had been kept at -80℃ until obtained at 
April 2016. The obtained 50mg of BLM standards were dissolved in DI-Water and stored 
in -80 degree in Celsius, which caused a problem of sample degradation for subsequent 
stability tests. BLM is a highly polar compound, which has high solubility in water and 
methanol, and neither would ensure that it would retain its stability stored in solvent. 
2.3 Calibration Curve Standard Preparation 
 BLM is very toxic and is delivered as a powder, so it is not suggested to prepare 
the solutions by weighing. The BLM analyte standard consisted of 50 mg of powder, and 
was directly dissolved in 1mL of DI-water. At the temperature of -80℃ for storage, water 
is more stable than that in methanol. As high concentration of methanol would need to 
precipitate proteins in plasma, further stock solutions would be prepared in 100% 
methanol. From the 1mL of 50mg/mL stock solutions, 50μL was vortexed and mixed 
with 49.95mL of 100% methanol to prepare a concentration of 50μg/mL secondary stock 
solution. From the secondary stock solution, 500μL was vortexed and mixed with 
49.5mL of 100% methanol to prepare a concentration of 500ng/mL stock solution. 20mL 
from the 500ng/mL stock solution was vortexed and mixed with 30mL of 100% methanol 
to prepare a concentration of 200ng/mL stock solution, and from which 5mL was 
vortexed and mixed with 45mL of 100% methanol to prepare a concentration of 20ng/mL 
stock solution. 500ng/mL, 200ng/mL, and 20ng/mL stock solutions were stored at -20℃ 
until use. 
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 0.5 mg of the internal standard VCM was vortexed and mixed with 1mL of 100% 
methanol to prepare the 0.5mg/mL main stock VCM solution, and from which 0.5mL 
was vortexed and mixed with 49.5mL of methanol to prepare the 5μg/mL secondary 
solution. All these stocks were stored at -80℃. 2mL of the 5μg/mL stock was vortexed 
and mixed with 48mL of methanol to prepare 200ng/mL of VCM stock, and which was 
stored at -20℃ until use. 
 As checked common bio-clinical treated plasma, there usually is 1.5-1.8mg/mL of 
EDTA treated, which is transferred as 4mM. The provided plasma samples were treated 
by 0.5M of EDTA. However, only to consider of the chelation between Cu
2+
 and EDTA 
(if there is any) by 1:1 ratio, 4mM of EDTA was prepared by dissolving 75.0mg of 
EDTA (molecular weight of 372.24g/mL) in 50mL of DI-water. 
 2mM of CuSO4·5H2O (molecular weight of 249.677) was prepared by dissolving 
25mg of solid CuSO4·5H2O in 50mL of DI-water. 
 To test selection and sensitivity of the method, the calibration standards were 
prepared as the final concentration of BLM from 1ng/mL, 5ng/mL, 10ng/mL, 20ng/mL, 
50ng/mL, 100ng/mL, and 200ng/mL. In the test period, plasma was replaced by DI-water 
to save the cost of plasma. To ensure the accuracy of concentration prepared, three BLM 
stock solutions were used to prepare corresponding standards. Final concentration of 
VCM was 40ng/mL. The solvent was prepared as 70% methanol. The calibration curve 
standards were prepared as shown in Table I. 
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BLM 
Stock 
conc. 
(ng/mL) 
 Blank 
Plasma or 
DI-water 
(μL) 
2mM 
CuSO4 
(μL) 
100% 
Methanol 
(μL) 
VCM 
(200ng/mL) 
(μL) 
BLM 
(μL) 
 Double 
Blank 
32 16 112   
 Blank 32 16 80 32  
20 1ng/mL 32 16 72 32 8 
5ng/mL 32 16 40 32 40 
10ng/mL 32 16 0 32 80 
200 20ng/mL 32 16 64 32 16 
50ng/mL 32 16 40 32 40 
100ng/mL 32 16 0 32 80 
500 200ng/mL 32 16 16 32 64 
20 LQC 
(2.5ng/mL) 
32 16 60 32 20 
200 MQC 
(20ng/mL) 
32 16 64 32 16 
500 LQC 
(160ng/mL) 
32 16 28.8 32 51.2 
Table I. Calibration Curve Standards Preparations. Concentration of 70% methanol was 
used to precipitate proteins from plasma. In the future research and method optimization, 
each standard would be ice-dried and dissolved in 20% methanol for instrumentation 
injection and detection. 
 
2.4 Protein Precipitation 
 All plasma samples were stored at -80℃ until use. After the working standards 
were prepared, they were vortexed for 1 minute, and then centrifuged at 14,000 rpm for 
15 minutes. Transferred 140μL of supernatant into vials with inserters and sent to the 
HPLC auto sampler for injection. 
 In the future research of optimization, each unit of supernatant was ice-dried and 
dissolved in 40μL of 20% methanol. Under this condition, the contents of standards 
preparation were changed. Prepared standards with concentrations of 1ng/mL, 20ng/mL, 
50ng/mL, 100ng/mL, and 500ng/mL in 100% methanol. The final methanol 
19 
concentration was changed to 80% to precipitate plasma proteins. The optimized 
standards were prepared as shown in Table II. 
 Blank 
Plasma or 
DI-water 
(μL) 
2mM CuSO4 
(μL) 
100% 
Methanol 
(μL) 
VCM 
(200ng/mL) 
(μL) 
BLM (μL) 
1ng/mL 32 16 160 32 2 
20ng/mL 32 16 160 32 2 
50ng/mL 32 16 160 32 2 
200ng/mL 32 16 160 32 2 
500ng/mL 32 16 160 32 2 
Table II. Optimized Standards Contents. This preparation plan was to optimize the 
protein precipitation and tried to higher the sensitivity of the method. However, in case of 
BLM stability reduce, it would not be used to make a calibration curve. 
 
2.5 HPLC-MS/MS Instrumentation 
 The instruments used were a HPLC and tandem quadrupole mass spectrometer 
system. The mass spectrometer was 5500 QTRAP triple quadrupole, tandem mass 
spectrometer (AB Sciex, Toronto, Canada). The high-performance liquid 
chromatography (HPLC, Shimadzu, Columbia, MD, USA) was composed of two LC-30 
AD pumps, DUG-20A3R inline degasser, a SIL-30 AC autosampler, a CBM-20A 
controller and a CTO-10AVP column oven (Shimdazu, Tokyo, Japan). 
2.6 HPLC-MS/MS Optimization Parameters 
 High-performance liquid chromatographic separation was carried using a Synergi 
4μ Hydro-RP 80A (50×2.00mm, 4 micron). The parameters of HPLC and MRM channel 
are shown in the Table III, IV, and V below. 
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Shimadzu LC System Equilibration Time 10.00 min 
Shimadzu LC System Injection Volume 5.00 μL 
Pump 
Pumping Mode Binary Flow 
Total Flow Rate 0.2 mL/min 
Pump B Concentration 5% 
Oven 
Temperature 40℃ 
Time Program 
0.01 min Pump B Concentration 20% 
2.00 min Pump B Concentration 50% 
9.50 min Pump B Concentration 60% 
9.51 min Pump B Concentration 2% 
10.00 min Stop 
Table III. Shimadzu LC System Parameters. 
 
 Q1 m/z Q3 m/z Collision 
Energy Start 
Collision 
Energy Stop 
BLM A2 739.0 707.7 40 40 
BLM B2 744.3 551.7 45 45 
VCM 725.9 100.2 47 47 
Table IV. MRM Fragmentation Transition in Positive Ion Mode. 
 
Ion Source Turbo Spray 
Curtain Gas (CUR) 40.0 
Collision Gas (CAD) High 
IonSpray Voltage (IS) 4500.0 
Temperature (TEM) 650.0 
Ion Source Gas 1 (GS1) 31.0 
Ion Source Gas 2 (GS2) 31.0 
Declustering Potential (DP) 60.0 
Entrance Potential (EP) 10.0 
Collision Cell Exit Potential (CXP) 13.0 
Table V. Optimized Mass Spectrometry Parameters.  
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CHAPTER III 
RESULTS AND DISCUSSIONS 
3.1 Method Application 
 Method validation according to FDA guidelines was not completed for this 
method. However, based on the completed method optimization, this method can 
quantify at least 0.2ng/mL of analyte concentration in plasma and standard calibrations 
curves with a correlation coefficient above 0.99 indicate the method indeed satisfies the 
requirements. The sensitivity is improved by solvent buffer optimization to increase 
injection volume and a concentration process to satisfy lower concentration analysis. As 
the BLM-Cu complex is more active in the mechanism of action, an appropriate amount 
of CuSO4 is added to enhance the components of BLM-Cu. One research group published 
an HPLC/MS/MS method to quantify Vancomycin, and in which mentioned to consider 
about using BLM as internal standards.
16
 This study used Vancomycin as the internal 
standard for BLM quantification successfully. The structure of Vancomycin is a 
glycoprotein, in which there are two sugar residues just like BLM. Also there lots of 
aromatic rings just like BLM. So the structures are very similar, which makes a good 
choice to make as an internal standard.  
3.2 Mass Spectrometry Results 
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3.2.1 Mass Spectrometry Q1 Infusion – BLM and VCM 
 In the Blenoxane that was obtained from Alexis Biochemicals, the main 
compositions are BLM A2 (67%) and BLM B2 (29%). The other compositions are shown 
in Table VI below. 
Bleomycin A2 67% 
Bleomycin B2 29% 
Demethylbleomycin A2 0.3% 
Bleomycin B4 0.03% 
Other Related Substances 3.5% 
Copper 109ppm 
Loss on Drying 2.5% 
Product Description Isolated from Streptomyces verticillus 
Table VI. Compositions in Blenoxane. 
 
The primary Q1 scan is shown in Figure 8 below. 
 
Figure 8. 1μg/mL BLM in 90% Methanol Q1 Scan. The B2 fraction, which is the more 
relevant biological form, in the spectra chelated with spiked excess of Cu(II) reduces the 
signal interference as it is almost completely converted to the copper-complex. 
 
The molecular weight of BLM A2 is 1414.52 and BLM B2 is 1424.56. To chelate 
with Cu
2+
, the corresponding molecular weights change to 1478.066 and 1489.206. The 
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m/z limit of the Qtrap instrument is 1250, therefore, the BLM A2 and B2 are present as 
their m/z of bivalence. 
 m/z 
BLM A2 708.0 
BLM B2 713.5 
BLM A2 – Cu
2+
 739.0 
BLM B2 – Cu
2+
 744.5 
Table VII. m/z of Each BLM Fractions in Spectrum with Q1 Channel. 
  
According to the spectrum, there is BLM A2 without chelating with Cu
2+
, which 
explains that BLM B2 has stronger chelation with Cu
2+
. In the future optimization, excess 
of Cu
2+
 from CuSO4 would be added to the standard preparation to transfer all BLM to 
BLM-Cu as much as possible. 
 
Figure 9. 500ng/mL VCM (725.4) in 70% Methanol Q1 Scan. 
 
3.2.2 Mass Spectrometrum Q1 Infusion – BLM and Cu Chelation 
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 According to the spectrum, BLM A2 has mostly transferred to BLM A2 – Cu 
chelation. However, to consider if there is reversible reaction on this chelation, a pair of 
comparative Q1 spectrums with time differentiation is shown in Figure 11 and Figure 12. 
 
Figure 10. BLM Q1 Scan without adding Excess of Cu
2+
. 
 
 
Figure 11. Excess of Cu
2+
 and BLM with Molecular Ratio of 50:1 at 3 minutes after 
Preparation. 
25 
 
Figure 12. Excess of Cu
2+
 and BLM with Molecular Ratio of 50:1 at 15 minutes after 
Preparation. 
  
In Figure 11 and Figure 12, it illustrates that the chelation between BLM and Cu 
has reversible possibility. At 3 minutes after the sample preparation, almost all BLM had 
been transferred into BLM – Cu complex. In the future study, the reaction condition is 
able to study, in which the temperature and pH value are changeable in primary. 
3.2.3 Mass Spectrometry Q1 Infusion – EDTA Interference 
 As all plasma samples are treated with EDTA, and EDTA might chelate metal 
ions to interfere the result of analysis, it is necessary to research if EDTA functions on 
chelation with Cu
2+
 in this method.  
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Figure 13. EDTA and BLM with Molecular Ratio of 50:1. 
  
According to the spectrums in Figure 10 and Figure 13, EDTA is rarely 
interfering the result. However, as BLM B2 is more active to chelate Cu than A2, the 
signal of BLM B2 – Cu is less than expected presence. There is no BLM B2 present in the 
spectrum, so that it is hard to explain whether EDTA is interfering B2. 
3.2.4 Mass Spectrometry Q2 Fragmentation – BLM and VCM 
 To identify the highest signals of fragments for BLM A2 and B2, two different 
collision energies were used for each of those fractions. The chosen fragment needs to be 
stably present to different collision energy, which indicates its stability and reliability.  
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Figure 14. Fragmentation of BLM A2 with Collision Energy of 40 and 46. 
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Figure 15. Fragmentation of BLM B2 with Collision Energy of 40 and 48. 
  
According to Figure 14 and Figure 15, the MRM transition of BLM A2 was m/z 
739.0 → 515.3, and BLM B2 was m/z 745.0 → 552.0. However, in a following LC-MRM 
test, there was a stronger signal of transition of BLM A2 was m/z 739.0 → 708.0. 
3.3 HPLC-MS/MS Results 
3.3.1 Selection of HPLC Column 
 As described before, BLM and VCM are polar compounds. Therefore, the best 
column for the HPLC analysis is a reverse phase column, and the mostly common choice 
would be a C18 column. However, according to a HPLC-MS/MS test (Figure 16), C18 
present peaks with obvious tailing issue, and the retentions were around 1 min, which 
would easily be indicated as an interference of solvent peak or impurities peak. In this 
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method, the final choice was a Synergi 4μ Hydro-RP 80A (50×2.00mm, 4 micron) 
column, from which the spectrum present good shapes of the peaks and retentions were 
all after 2 minutes (Figure 17). 
 
Figure 16. HPLC Chromatogram of BLM A2 and B2 Using a C18 Column. 
 
 
Figure 17. HPLC Chromatogram of BLM A2 and B2 Using a Synergi Hydro-RP C18 
Column. 
 
BLM A2 Has Retention Time at ~0.6min 
BLM B2 Has Retention Time at 0.99min 
BLM A2, Retention at 2.46min 
BLM B2, Retention at 2.67min 
VCM, 
Retention at 
2.22min 
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3.3.2 Methanol Percentage in the Sample 
 Calibration standards solvent has the ability to affect the retention and elution of 
analytes subjected to HPLC. To make the standard preparation simple, the calibration 
standards were prepared in methanol and DI-water plus Cu
2+
 in addition. Previous 
research in the literature used 75-90% methanol as the HPLC solvents with their C18 
columns.
4, 17, 18
 However, in this method with 5μL of injection volume, it appeared to be 
difficult to retain by using 70% methanol, which is shown in Figure 18. In Figure 18, it 
shows that all analytes and internal standard indicate on retention time of 0.87 minutes. 
As use of 20% methanol in Figure 19, the problem of retention has been solved, even 
when changed to a higher volume injection of 20μL. 
  
Figure 18. HPLC Chromatogram of 200ng/mL BLM in 70% methanol. 
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Figure 19. HPLC Chromatogram of 200ng/mL BLM in 20% methanol. 
 
3.3.3  Mass Chromatograms of Standards Preparation from Table I 
 The standards were prepared according to Table I, and then protein was 
precipitated. 100μL aliquots of the supernatant were ice-dried, and 100μL of 20% 
methanol was added to dissolve. The resulting mass chromatograms are shown in Figures 
20-26. BLM A2 had a retention time of 2.4 minutes, BLM B2 had a retention time of 2.7 
minutes, and VCM had a retention time of 2.2 minutes. 
 
Figure 20. Mass Chromatogram of 1ng/mL of BLM and 40ng/mL of VCM in Plasma. 
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Figure 21. Mass Chromatogram of 5ng/mL of BLM and 40ng/mL of VCM in Plasma. 
 
 
Figure 22. Mass Chromatogram of 10ng/mL of BLM and 40ng/mL of VCM in Plasma. 
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Figure 23. Mass Chromatogram of 20ng/mL of BLM and 40ng/mL of VCM in Plasma. 
 
 
Figure 24. Mass Chromatogram of 50ng/mL of BLM and 40ng/mL of VCM in Plasma. 
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Figure 25. Mass Chromatogram of 100ng/mL of BLM and 40ng/mL of VCM in Plasma. 
 
 
Figure 26. Mass Chromatogram of 200ng/mL of BLM and 40ng/mL of VCM in Plasma. 
 
3.3.4  Calibration Curve of Standards Preparation from Table I 
 The calibration curves were constructed using seven calibration standards. The 
linear calibration range was between 1-200 ng/mL. The calibration curve for rats’ plasma 
spiked with BLM and VCM is shown in Figure 27 and 28. 
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Figure 27. Calibration of BLM A2. 
 
  
Figure 28. Calibration of BLM B2.  
y = 0.205 x - 0.206 
r = 0.9906 
y = 0.00778 x + 0.00662 
r = 0.9955 
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CHAPTER IV 
CONCLUSION 
 Bleomycin quantitative analysis had been developed by spiking excess of Cu
2+
 to 
transfer BLM into BLM-Cu complex, solving the problem of using mixed standards with 
exact percentage of each component to quantify clinical samples and eliminating the need 
for sophisticated higher resolution instruments that are costly to the lab. Simple 
chromatography conditions of solvent buffer was optimized, which makes future study of 
BLM metabolism and mechanism achievable.  
 In the future study of BLM, it is necessary to find the activity of each of BLM A2 
and B2 fraction binding to Cu or other metal ions. From the calibration curves that were 
made during the entire research, it is obvious that the BLM B2 is more active to bind with 
Cu, which was present in their spectrums of mass spectrometry Q1 scan and the quantity 
in calibration curves. However, the stability of the complexes would also be worth to 
research. Unfortunately, due to sample degradation, the method validation could not be 
completed in this work, however sensitivity and selectivity on the samples for the method 
development cohort revealed higher sensitivity and selectivity than previously published 
methods. 
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